|Esperion to Provide ETC-1002 Program Update; Inovio Announces Public Offering of Common Stock|
|By Staff and Wire Reports|
|Wednesday, 26 February 2014 20:26|
Esperion Therapeutics (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, announced it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
The call can be accessed by dialing (877) 312-7508 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing access code 56291756. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.esperion.com/events. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.
Inovio Pharmaceuticals, Inc. ((NYSEMKT: INO) announced it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission on February 13, 2014. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at [email protected]; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720 or email at [email protected]
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2013.
Anavex Life Sciences Corp. (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds.
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year-ended December 31, 2013.
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, today announced that the United States Patent and Trademark Office (USPTO) has allowed its patent claims related to the Company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample.
CAS Medical Systems, Inc. (Nasdaq:CASM), a leader in medical devices for non-invasive patient monitoring, today announced that Thomas M. Patton, President and Chief Executive Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. PT.
Dehaier Medical Systems Ltd. (Nasdaq:DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced the closing of a previously announced securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors for the sale of 734,700 common shares in a registered offering at the price of $9.12 per common share.
Digirad Corporation (Nasdaq:DRAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million.
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy (the ProHema-01 trial).
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease."
Global Links Corp. (OTC:GLCO), today announced that the Company's wholly-owned subsidiary, Hemp Life Today, LLC, has launched a proprietary business networking platform for the Cannabis industry called CannaMove.com.
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, 3 March, 2014 at 3:30 p.m. ET.
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Cowen and Company 34th Annual Healthcare Conference on Monday, March 3 at 2:50 p.m. ET.
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, awarded inducement grants to Vivek Jain, Chief Executive Officer.
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company will present at Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 11:20 a.m. Eastern Time in Boston, Massachusetts.
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of U.S. Patent No. 8,658,773, which protects a method of concentrating antibodies for subcutaneous, intramuscular or transdermal administration.
MedAssets, Inc. (Nasdaq:MDAS) today announced results for its fourth quarter and twelve-month period ended December 31, 2013.
MedAssets, Inc. (Nasdaq:MDAS) today announced that its Board of Directors has authorized the repurchase of up to $75 million of the company's common stock over the next twelve months.
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the three and twelve months ended December 31, 2013.
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products, announced today that it has entered into an exclusive distribution agreement with Principle Business Enterprises (PBE).
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference.
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA.
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34th Annual Health Care Conference in Boston, Massachusetts.
PositiveID Corporation (OTCQB:PSID), a developer of biological threat detection and diagnostics solutions, today provided a review of its 2013 accomplishments and its outlook for 2014.
RCM Technologies, Inc. (Nasdaq:RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced information technology, engineering and specialty health care services, today announced financial results for the thirteen and fifty-two week periods ended December 28, 2013.
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview of the company at the Cowen & Co. 34th Annual Health Care Conference in Boston, MA on March 4 at 10:40 am ET and at the 26th Annual ROTH Conference in Dana Point, CA on March 10 at 5:00 pm PT.
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ended December 31, 2013.
Sabra Health Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) today announced results of operations for the fourth quarter of 2013.
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 9:20 AM ET.
Strategic Rare Earth Metals, Inc. (OTC Markets:SREH) announced today that the Company is taking a 100% direction into the Medical Marijuana field and has received numerous proposals from parties involved in the Cannabis Industry.
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its fourth quarter and year-end 2013 results will be released on Tuesday, March 11, 2014, before the open of the stock market.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014 at 11:20am ET at the Boston Marriott Copley Place.
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34th Annual Cowen Health Care Conference (Boston, Massachusetts March 3 – 5).